(RS)-troglitazone
Sign in to saveTroglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2.
Research
11 papers- Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol.Pharmaceutics · 2021
- Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.Hypertension research : official journal of the Japanese Society of Hypertension · 2001
- Physical property of troglitazone, an equal mixture of four stereoisomers.International journal of pharmaceutics · 2002
- Activation of PPARG inhibits dominant follicle development in cattle.Theriogenology · 2020
- Solid-state variation of troglitazone drug substance by using a different recrystallization method.Drug development and industrial pharmacy · 2003
via PubMed
Article
6 sectionsContents
- Mechanism of action
- History
- Mechanisms of hepatotoxicity
- Lawsuits
- References
- External links
Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2.
It was patented in 1983 and approved for medical use in 1997. It was subsequently withdrawn.
Gallery (2)
Connections
Categories
3β-Hydroxysteroid dehydrogenase inhibitorsAromatase inhibitorsChromanesCYP17A1 inhibitorsCYP3A4 inducersDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by Parke-DavisDrugs with non-standard legal statusHepatotoxinsPhenol ethersThiazolidinediones